Mucin-2 Expression in Primary and Recurrent Cases of Pleomorphic Adenoma in Tertiary Care Hospitals of Peshawar
DOI:
https://doi.org/10.36283/PJMD13-2/003Keywords:
Mucin-2, Pleomorphic Adenoma, Salivary Gland NeoplasmsAbstract
Background: Pleomorphic adenoma (PA) is a benign tumor, with a high recurrence rate. This study aimed to compare the Mucin-2 (MUC2) expression in primary and recurrent cases of PA in tertiary care hospitals of Peshawar.
Methods: In this study, there were 60 PA cases, 51 being primary lesions and 9 recurrent lesions. Formalin-fixed and paraffin-embedded (FFPE) blocks of the two groups were examined for the immunohistochemical expression of MUC2. The clinicopathological parameters were also examined. This study was conducted at the Pathology Department, Pakistan Institute of Medical Sciences (PIMS), Peshawar, between January 2019 to January 2021. A nonprobability sampling technique was used while collecting the samples. SPSS version 21 was used and p-value<0.05 was considered significant.
Results: The mean age was 32.3±8 years for both primary and recurrent PA cases. Out of the total, there were 30 (50%) females with 21 (35%) males, while all the recurrent cases were females 9 (15%). Most common microscopic features evaluated by H&E-staining showed Myxoid and chondroid stroma along with sheets of epithelioid and basaloid cells. Among 51 cases of primary PA, 17 (33%) showed positive MUC2 expressions and 34 (66.6%) showed negative expressions while all cases of recurrent PA showed positive MUC2 expression with a p-value of 0.05. In primary PA, only a single (1.66%) case showed a strong stain, while there were 5(55.3%) cases in the recurrent PA.
Conclusion: The expression of MUC2 is a useful marker to predict recurrence and there was a significant difference in the expression of MUC2 in primary and recurrent cases of PA.
References
Zhan KY, Khaja SF, Flack AB, Day TA. Benign parotid tumors. Otolaryngol Clin North Am. 2016;49(2):327–342. http://dx.doi.org/10.1016/j.otc.2015.10.005
Iqbal F, Bashir N, Saleem A, Khan MM, Naushin T, Alam S, et al. Why Do Parotid PAs Recur? A Systematic Review of Pathological and Surgical Variables. Front Surg. Archives of Craniofacial Surgery. 2017;26(10). http://dx.doi.org/10.29309/TPMJ/2019.26.10.2782
Park SY, Han K-T, Kim M-C, Lim JS. Recurrent pleomorphic adenoma of the parotid gland. Arch Craniofac Surg. 2016;17(2):90. http://dx.doi.org/10.7181/acfs.2016.17.2.90
Dulguerov P, Todic J, Pusztaszeri M, Alotaibi NH. Why Do Parotid Pleomorphic Adenomas Recur? A Systematic Review of Pathological and Surgical Variables. Front Surg. 2017; 4:26. doi: 10.3389/fsurg.2017.00026.
Bu X-D. Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol. 2010;16(32):4089. http://dx.doi.org/10.3748/wjg.v16.i32.4089
Werner RL, Castle JT. Recurrent pleomorphic adenoma. Head Neck Pathol. 2014;8(3):303–306. http://dx.doi.org/10.1007/s12105-013-0504-6
Hamada T, Matsukita S, Goto M, Kitajima S, Batra SK, Irimura T, et al. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. Journal of clinical pathology. 2021;57(8):813–821. http://dx.doi.org/10.1016/j.ijom.2013.02.012
Zbären P, Zbären S, Caversaccio MD, Stauffer E. Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome. Otolaryngol Head Neck Surg. 2008;138(5):601–605. http://dx.doi.org/10.1016/j.otohns.2008.01.013
Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis trans-membrane regulator dependant bicarbonate secretion. J Clin Invest. 2019; 119:2613–2622.
Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol. 1985;146(1):51–58. http://dx.doi.org/10.1002/path.1711460106
Hamada T, Matsukita S, Goto M, Kitajima S, Batra SK, Irimura T, et al. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J Clin Pathol. 2004;57(8):813–821. http://dx.doi.org/10.1136/jcp.2003.014043
Valstar MH, de Ridder M, van den Broek EC, Stuiver MM, van Dijk BAC, van Velthuysen MLF, et al. Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol. 2017; 66:93–99. http://dx.doi.org/10.1016/j.oraloncology.2017.01.004
Aro K, Valle J, Tarkkanen J, Mäkitie A, Atula T. Repeatedly recurring pleomorphic adenoma: a therapeutic challenge. Acta Otorhinolaryngol Ital. 2019;39(3):156–161. http://dx.doi.org/10.14639/0392-100x-2307
Riad MA, Abdel-Rahman H, Ezzat WF, Adly A, Dessouky O, Shehata M. Variables related to recurrence of pleomorphic adenomas: outcome of parotid surgery in 182 cases. Laryngoscope. 2011;121(7):1467–1472. http://dx.doi.org/10.1002/lary.21830
Witt RL, Eisele DW, Morton RP, Nicolai P, Poorten VV, Zbären P. Etiology and management of recurrent parotid pleomorphic adenoma: Management of Recurrent Pleomorphic Adenoma. Laryngoscope. 2015;125(4):888–893. http://dx.doi.org/10.1002/lary.24964
Bankamp DG, Bierhoff E. Proliferative activity in recurrent and nonrecurrent pleomorphic adenoma of the salivary glands. Laryngorhinootologie. 1999;78(2):77–80. http://dx.doi.org/10.1055/s-2007-996835
Xu YQ, Li C, Fan JC, Zhang B, Chen JC, Wang ZH. Evidence for determining the safe surgical margin for pleomorphic adenoma of parotid gland. 2012; 47:137–141. http://dx.doi.org/10.3760/cma.j.issn.1673-0860.2012.02.011
Godl K, Johansson M, Karlsson H. The N-termini of the MUC2 mucin form trimers that are held together within a trypsin-resistant core fragment. J Biol Chem. 2015; 277:47248–47256.
Phillips PP, Olsen KD. Recurrent pleomorphic adenoma of the parotid gland: report of 126 cases and a review of the literature. Ann Otol Rhinol Laryngol. 1995;104(2):100–104. http://dx.doi.org/10.1177/000348949510400203
Kalwaniya DS, Meena R, Kumar D, Tolat A, Arya SV. A review of the current literature on pleomorphic adenoma. Cureus. 2023;15(7):e42311. http://dx.doi.org/10.7759/cureus.42311
Fung K-M, Diaz EM Jr, El-Naggar AK, Luna MA. Malignant rhabdoid tumor arising from a pleomorphic adenoma. Ann Diagn Pathol. 2004;8(3):156–161. http://dx.doi.org/10.1016/j.anndiagpath.2004.03.008
Mannweiler S, Beham A, Langner C. MUC1 and MUC2 expression in salivary gland tumors and in non-neoplastic salivary gland tissue. APMIS. 2003;111(10):978–984. http://dx.doi.org/10.1034/j.1600-0463.2003.1111010
Zhan KY, Khaja SF, Flack AB, Day TA. Benign Parotid Tumors. Otolaryngol Clin North Am. 2016;49(2):327-342. doi: 10.1016/j.otc.2015.10.005.
Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J Clin Pathol. 2004;57(8):813–821. http://dx.doi.org/10.1136/jcp.2003.014043
Vighi G, Marcucci F, Sensi L, Di Cara G, Frati F. Allergy and the gastrointestinal system. Clin Exp Immunol. 2008;153 Suppl 1(Suppl 1):3-6. doi: 10.1111/j.1365-2249.2008.03713.x.
van Putten JPM, Strijbis K. Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer. J Innate Immun. 2017;9(3):281-299. doi: 10.1159/000453594.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
